MULTIPLE MYELOMA

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.

George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.

Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.

During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.

In a comparison of 2 live events from the Targeted Oncology Case-Based Roundtable series, we look at how adding daratumumab to therapy for patients with newly diagnosed disease who cannot receive a transplant has shifted the approach to treatment.

Leo Shunyakov, MD, discussed long-term treatments and trials for patients with newly diagnosed multiple myeloma.

George Nahas, DO, discusses recent and ongoing research that has impacted the current treatment landscape for patients with multiple myeloma.

In an interview with Targeted Oncology, Yael C. Cohen, MD, senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the results from RedirecTT-1 she presented at ASCO 2023.

Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed second-line therapy combinations for a patient with early-relapse multiple myeloma after complete remission with bortezomib, lenalidomide, and dexamethasone.

During a Targeted Oncology™ Case-Based Roundtable™ event, Chakra P. Chaulagain, MD, and participants discussed how they would treat a 54-year-old woman diagnosed with transplant-eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.

In the second article of a 2-part series, Alfred Garfall, MD, discussed how to best treat patients with multiple myeloma after they undergo transplant and whether continuing quadruplet therapy can provide a benefit before maintenance therapy.

In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.

In separate, live virtual events, Jonathan L. Kaufman, MD, and Morie A. Gertz, MD, MACP, discussed concerns about using chimeric antigen receptor T-cell therapy for a patient with relapsed/refractory multiple myeloma who is experiencing rapid disease progression.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Binod Dhakal, MD, MS, and participants discussed which treatment should come next for a patient with relapsed multiple myeloma depending on the patient's ability to travel for care.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.

Although dosing will continue in iMMagine-1 for patients who responded well to CART-ddBCMA, recruitment has been halted due to to a safety concern.

REGN5459 led to positive responses among patients with multiple myeloma, according to findings from a first-in-human phase 1/2 trial.

Mohamad Mohty, MD, PhD, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma.

A newly authorized phase 1b study will evaluate the safety and efficacy of the continuous delivery of lenalidomide among patients with multiple myeloma.

In part 1 of a 2-part series, Alfred L. Garfall, MD, leads a discussion in the use of adding daratumumab to triplet therapy for patients with multiple myeloma.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

Teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, says María-Victoria Mateos, MD, PhD.